Association between brain amyloid deposition and longitudinal changes of white matter hyperintensities.

Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101511643 Publication Model: Electronic Cited Medium: Internet ISSN: 1758-9193 (Electronic) NLM ISO Abbreviation: Alzheimers Res Ther Subsets: MEDLINE

Original Publication: [London] : BioMed Central Ltd.

Alzheimer Disease*/pathology ; White Matter*/diagnostic imaging ; White Matter*/pathology ; Cognitive Dysfunction*/pathology; Humans ; Male ; Female ; Aged ; Amyloid beta-Peptides/metabolism ; Brain/metabolism ; Magnetic Resonance Imaging

Background: Growing evidence suggests that not only cerebrovascular disease but also Alzheimer's disease (AD) pathological process itself cause cerebral white matter degeneration, resulting in white matter hyperintensities (WMHs). Some preclinical evidence also indicates that white matter degeneration may precede or affect the development of AD pathology. This study aimed to clarify the direction of influence between in vivo AD pathologies, particularly beta-amyloid (Aβ) and tau deposition, and WMHs through longitudinal approach.
Methods: Total 282 older adults including cognitively normal and cognitively impaired individuals were recruited from the Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease (KBASE) cohort. The participants underwent comprehensive clinical and neuropsychological assessment, [ ¹¹ C] Pittsburgh Compound B PET for measuring Aβ deposition, [ ¹⁸ F] AV-1451 PET for measuring tau deposition, and MRI scans with fluid-attenuated inversion recovery image for measuring WMH volume. The relationships between Aβ or tau deposition and WMH volume were examined using multiple linear regression analysis. In this analysis, baseline Aβ or tau were used as independent variables, and change of WMH volume over 2 years was used as dependent variable to examine the effect of AD pathology on increase of WMH volume. Additionally, we set baseline WMH volume as independent variable and longitudinal change of Aβ or tau deposition for 2 years as dependent variables to investigate whether WMH volume could precede AD pathologies.
Results: Baseline Aβ deposition, but not tau deposition, had significant positive association with longitudinal change of WMH volume over 2 years. Baseline WMH volume was not related with any of longitudinal change of Aβ or tau deposition for 2 years. We also found a significant interaction effect between baseline Aβ deposition and sex on longitudinal change of WMH volume. Subsequent subgroup analyses showed that high baseline Aβ deposition was associated with increase of WMH volume over 2 years in female, but not in male.
Conclusions: Our findings suggest that Aβ deposition accelerates cerebral WMHs, particularly in female, whereas white matter degeneration appears not influence on longitudinal Aβ increase. The results also did not support any direction of influence between tau deposition and WMHs.
(© 2024. The Author(s).)

Neuroscience. 2010 Aug 11;169(1):516-31. (PMID: 20434528)
Glia. 2011 Apr;59(4):627-40. (PMID: 21294162)
Brain. 2019 Mar 1;142(3):771-786. (PMID: 30668647)
Acta Neuropathol. 2017 Sep;134(3):459-473. (PMID: 28638989)
Neurology. 2020 Mar 3;94(9):e950-e960. (PMID: 31888969)
Acta Neuropathol Commun. 2015 Sep 30;3:60. (PMID: 26419828)
Alzheimers Dement. 2017 Oct;13(10):1154-1167. (PMID: 28322203)
J Int Neuropsychol Soc. 2004 Jan;10(1):72-81. (PMID: 14751009)
Neurobiol Aging. 2019 Dec;84:225-234. (PMID: 31500909)
Front Neuroendocrinol. 2009 Jul;30(2):239-58. (PMID: 19427328)
Neuroimage. 2020 Sep;218:116944. (PMID: 32445880)
Neurology. 2022 Jul 12;99(2):e129-e141. (PMID: 35410910)
PLoS One. 2013;8(2):e54722. (PMID: 23431360)
Alzheimers Dement. 2022 Mar;18(3):422-433. (PMID: 34322985)
Curr Opin Psychiatry. 2018 Mar;31(2):147-152. (PMID: 29232251)
Alzheimers Dement (Amst). 2022 Nov 03;14(1):e12369. (PMID: 36348973)
Alzheimers Dement. 2011 May;7(3):270-9. (PMID: 21514249)
Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6820-5. (PMID: 19346482)
Neuroimage. 2002 Jan;15(1):273-89. (PMID: 11771995)
J Affect Disord. 2003 Mar;74(1):67-83. (PMID: 12646300)
Glia. 2009 Jan 1;57(1):54-65. (PMID: 18661556)
Brain. 2019 Aug 1;142(8):2483-2491. (PMID: 31199475)
J Biol Chem. 2009 Oct 16;284(42):28917-25. (PMID: 19692707)
Nat Rev Neurol. 2015 Mar;11(3):157-65. (PMID: 25686760)
PLoS One. 2014 Aug 15;9(8):e104011. (PMID: 25127120)
Alzheimers Dement (Amst). 2020 Oct 13;12(1):e12091. (PMID: 33083512)
Neurology. 2004 Jul 27;63(2):220-7. (PMID: 15277612)
Lancet. 1991 May 11;337(8750):1158-9. (PMID: 1674030)
Nat Rev Nephrol. 2018 Mar;14(3):185-201. (PMID: 29380817)
Neuroimage. 2016 Jan 1;124(Pt A):724-732. (PMID: 26385011)
Neurobiol Aging. 2018 Feb;62:231-242. (PMID: 29195086)
Neurology. 2018 Jul 24;91(4):e313-e318. (PMID: 29959265)
J Nucl Med. 2018 Oct;59(10):1583-1589. (PMID: 29674420)
Neurobiol Aging. 2020 Jul;91:5-14. (PMID: 32305782)
Curr Opin Psychiatry. 2013 May;26(3):244-51. (PMID: 23493128)
Neurology. 2022 Aug 30;99(9):e935-e943. (PMID: 35768207)
Neurobiol Aging. 2017 Aug;56:172-179. (PMID: 28552181)
J Gerontol B Psychol Sci Soc Sci. 2002 Jan;57(1):P47-53. (PMID: 11773223)
J Alzheimers Dis. 2020;78(1):13-22. (PMID: 32925075)
J Biol Chem. 2011 Feb 4;286(5):3693-706. (PMID: 20971854)
Alzheimers Dement. 2017 Mar;13(3):205-216. (PMID: 27697430)
Brain Commun. 2020 Aug 19;2(2):fcaa132. (PMID: 33215083)
Psychiatry Investig. 2017 Nov;14(6):851-863. (PMID: 29209391)
Acta Neuropathol Commun. 2019 Aug 20;7(1):135. (PMID: 31429800)
Acta Neuropathol. 2016 May;131(5):645-58. (PMID: 26711459)
Alzheimers Dement. 2011 May;7(3):263-9. (PMID: 21514250)
Neurobiol Dis. 2022 Jun 15;168:105714. (PMID: 35358703)
Neuroimage. 2017 Jan 1;144(Pt A):113-127. (PMID: 27577718)

U01 AG072177 United States AG NIA NIH HHS

Keywords: Alzheimer’s disease; Beta-amyloid; Sex difference; Tau; White matter hyperintensity

0 (Amyloid beta-Peptides)

Date Created: 20240308 Date Completed: 20240311 Latest Revision: 20240712

20240712

PMC10918927

10.1186/s13195-024-01417-8

38454444